JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3626
CALL
US Bancorp Series B Preferred Stock
USB.PRH
$733M
| $884K | ﹤0.01% |
16,500
-58,100
| -78% | -$1.33M |
2016 Q4
4 quarters
|
|
|
BERY
3627
PUT
DELISTED
Berry Global Group, Inc.
BERY
| $880K | ﹤0.01% |
+16,335
| New | +$889K |
2017 Q4
0 quarters
|
|
3628
CALL
Microchip Technology
MCHP
$42.6B
| $879K | ﹤0.01% |
+20,000
| New | +$905K |
2017 Q4
0 quarters
|
|
|
MNR
3629
DELISTED
Monmouth Real Estate Investment Corp
MNR
| $879K | ﹤0.01% |
49,366
+13,861
| +39% | +$240K |
2015 Q2
10 quarters
|
|
3630
PUT
United States Natural Gas Fund
UNG
$515M
| $875K | ﹤0.01% |
9,375
| – | – |
2017 Q3
1 quarter
|
|
3631
iShares Dow Jones US ETF
IYY
$3.03B
| $874K | ﹤0.01% |
13,088
-116
| -0.9% | -$7.56K |
2013 Q2
18 quarters
|
|
|
CALD
3632
DELISTED
Callidus Software, Inc.
CALD
| $873K | ﹤0.01% |
30,444
+25,451
| +510% | +$694K |
2015 Q4
8 quarters
|
|
3633
Invesco Building & Construction ETF
PKB
$284M
| $868K | ﹤0.01% |
25,021
-36,407
| -59% | -$1.21M |
2016 Q2
6 quarters
|
|
|
BEAT
3634
DELISTED
BioTelemetry, Inc.
BEAT
| $868K | ﹤0.01% |
29,030
+6,666
| +30% | +$193K |
2016 Q3
5 quarters
|
|
3635
WisdomTree Emerging Markets SmallCap Dividend Fund
DGS
$1.69B
| $864K | ﹤0.01% |
16,566
+3,879
| +31% | +$193K |
2017 Q2
2 quarters
|
|
|
NGHC
3636
DELISTED
National General Holdings Corp
NGHC
| $864K | ﹤0.01% |
43,975
+13,976
| +47% | +$286K |
2015 Q2
10 quarters
|
|
|
CLLS
3637
Cellectis
CLLS
$141M
| $862K | ﹤0.01% |
29,565
+10,755
| +57% | +$293K |
2017 Q3
1 quarter
|
|
3638
QuinStreet
QNST
$854M
| $862K | ﹤0.01% |
102,821
+6,196
| +6% | +$52.6K |
2016 Q3
5 quarters
|
|
3639
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.42B
| $857K | ﹤0.01% |
27,611
-1,092
| -4% | -$33.5K |
2017 Q1
3 quarters
|
|
3640
iShares Global Healthcare ETF
IXJ
$4.25B
| $857K | ﹤0.01% |
15,246
-1,300
| -8% | -$73.1K |
2014 Q4
12 quarters
|
|
|
CVA
3641
DELISTED
Covanta Holding Corporation
CVA
| $855K | ﹤0.01% |
50,597
+26,396
| +109% | +$408K |
2013 Q2
18 quarters
|
|
3642
MiMedx Group
MDXG
$677M
| $853K | ﹤0.01% |
67,647
+21,104
| +45% | +$257K |
2015 Q4
8 quarters
|
|
3643
CALL
Synopsys
SNPS
$94B
| $852K | ﹤0.01% |
+10,000
| New | +$865K |
2017 Q4
0 quarters
|
|
3644
TechTarget
TTGT
$268M
| $852K | ﹤0.01% |
61,228
+1,828
| +3% | +$23.8K |
2016 Q2
6 quarters
|
|
|
CLD
3645
DELISTED
Cloud Peak Energy Inc
CLD
| $850K | ﹤0.01% |
+191,113
| New | +$803K |
2017 Q4
0 quarters
|
|
|
SRDX
3646
DELISTED
Surmodics
SRDX
| $849K | ﹤0.01% |
30,303
+14,875
| +96% | +$454K |
2013 Q2
18 quarters
|
|
3647
Collegium Pharmaceutical
COLL
$711M
| $848K | ﹤0.01% |
45,935
+27,516
| +149% | +$394K |
2017 Q3
1 quarter
|
|
|
OSG
3648
Octave Specialty Group
OSG
$194M
| $847K | ﹤0.01% |
53,006
-150,450
| -74% | -$2.31M |
2013 Q2
18 quarters
|
|
3649
AXT Inc
AXTI
$5.36B
| $847K | ﹤0.01% |
97,373
+74,705
| +330% | +$683K |
2017 Q3
1 quarter
|
|
|
GNC
3650
PUT
DELISTED
GNC Holdings, Inc.
GNC
| $847K | ﹤0.01% |
229,600
+213,500
| +1,326% | +$1.34M |
2015 Q4
8 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.